Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17262215rdf:typepubmed:Citationlld:pubmed
pubmed-article:17262215lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:17262215lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17262215lifeskim:mentionsumls-concept:C0011923lld:lifeskim
pubmed-article:17262215lifeskim:mentionsumls-concept:C0005919lld:lifeskim
pubmed-article:17262215lifeskim:mentionsumls-concept:C0034595lld:lifeskim
pubmed-article:17262215lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:17262215lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:17262215lifeskim:mentionsumls-concept:C1527240lld:lifeskim
pubmed-article:17262215lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:17262215lifeskim:mentionsumls-concept:C2001032lld:lifeskim
pubmed-article:17262215pubmed:issue8lld:pubmed
pubmed-article:17262215pubmed:dateCreated2007-8-21lld:pubmed
pubmed-article:17262215pubmed:abstractTextWe aimed at designing and developing a novel bombesin analogue, DOTA-PEG(4)-BN(7-14) (DOTA-PESIN), with the goal of labelling it with (67/68)Ga and (177)Lu for diagnosis and radionuclide therapy of prostate and other human cancers overexpressing bombesin receptors.lld:pubmed
pubmed-article:17262215pubmed:languageenglld:pubmed
pubmed-article:17262215pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17262215pubmed:citationSubsetIMlld:pubmed
pubmed-article:17262215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17262215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17262215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17262215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17262215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17262215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17262215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17262215pubmed:statusMEDLINElld:pubmed
pubmed-article:17262215pubmed:monthAuglld:pubmed
pubmed-article:17262215pubmed:issn1619-7070lld:pubmed
pubmed-article:17262215pubmed:authorpubmed-author:ReubiJean...lld:pubmed
pubmed-article:17262215pubmed:authorpubmed-author:EisenhutMicha...lld:pubmed
pubmed-article:17262215pubmed:authorpubmed-author:MaeckeHelmut...lld:pubmed
pubmed-article:17262215pubmed:authorpubmed-author:WaserBeatrice...lld:pubmed
pubmed-article:17262215pubmed:authorpubmed-author:WildDamianDlld:pubmed
pubmed-article:17262215pubmed:authorpubmed-author:SchuhmacherJo...lld:pubmed
pubmed-article:17262215pubmed:authorpubmed-author:ZhangHanwenHlld:pubmed
pubmed-article:17262215pubmed:issnTypePrintlld:pubmed
pubmed-article:17262215pubmed:volume34lld:pubmed
pubmed-article:17262215pubmed:ownerNLMlld:pubmed
pubmed-article:17262215pubmed:authorsCompleteYlld:pubmed
pubmed-article:17262215pubmed:pagination1198-208lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:meshHeadingpubmed-meshheading:17262215...lld:pubmed
pubmed-article:17262215pubmed:year2007lld:pubmed
pubmed-article:17262215pubmed:articleTitleDOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.lld:pubmed
pubmed-article:17262215pubmed:affiliationDivision of Radiological Chemistry, Department of Radiology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.lld:pubmed
pubmed-article:17262215pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17262215pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17262215lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17262215lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17262215lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17262215lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17262215lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17262215lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17262215lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17262215lld:pubmed